Asundexian
For many patients, ‘a major bleed is any bleed that happens to me’
Despite advances in anticoagulant therapies, bleeding remains a critical concern.
Asundexian did not prevent stroke, systemic embolism vs. apixaban in atrial fibrillation
Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.
Q&A: Failure of OCEANIC-AF trial may not dampen future of factor XI/XIa inhibitors
Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.
Asundexian gains fast track designation for stroke prevention in patients with AF
Bayer announced the FDA has granted fast track designation for asundexian — a once-daily oral factor XIa inhibitor — for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Asundexian may not prevent second stroke after small subcortical infarct
A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those with small subcortical infarcts.
Asundexian inhibits factor XIa activity with no excess bleeding risk after MI, stroke
Asundexian on top of dual antiplatelet therapy successfully reduced factor XIa activity after acute MI and stroke with no excess bleeding risk, two speakers reported.